Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Cue Biopharma, Inc.CUE · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $42.2M[1]
Standard universeinsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, short runway, thin data · fortress balance sheetnot computable: distress
Inputs computable6 of 14
Graded fromfilings received through Mar 16, 2026207 days before the rescan; every figure keyed to the SEC receipt date
Last close$22.162026-10-08; market equity $161.0M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$20$40NovDecJanFebMarAprMayJunJulAugSepOct$22.33
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2019nonen/aQ2
Apr 21, 2024D70.1Q2
Apr 21, 2025nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 16, 2026; the document on sec.gov.

We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. Unlike conventional approaches that broadly activate the immune system, our Immuno-STAT® platform is designed to selectively modulate disease-relevant T cells, enhancing efficacy while minimizing off-target effects. We believe our Immuno-STAT platform holds the promise of producing drug product candidates with the potential of establishing new standards of care in the treatment of autoimmune and inflammatory diseases.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 58.0%[3-4]
Short runway. cash runway is 4.2 months[5]
Thin data. 6 of 14 grade factors are computable; minimum is 7
Fortress balance sheet. cash minus debt is 44,514,000 USD; Altman Z is not used[6-7]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 33.6
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
a prior annual debt, equity, and cash observation is required
Accruals ratio(13.2%)[1,8-10](6.6%)33.68112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 68.9
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime(27.27)[1,11-16](0.31)78.77562025-12-31
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
interest expense must exceed $100,000
Current ratio2.74x[11-12]2.96x59.28392025-12-31
Growth and financing, sleeve percentile 55.6
Revenue growth, three-year compound180.5%[2,17-19]10.0%1.94152025-12-31
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years(22.7%)[1,10,20-21]2.1%86.37042025-12-31
Net share issuance, one year58.0%[3-4]2.5%78.56342026-03-13

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month18.4%8.0%58hotter than 58 of 100 peers
Distance from 52-week high(41.0%)(31.4%)37closer to its high than 37 of 100 peers
EBIT to enterprise value(18.2%)(1.5%)25pricier than 75 of 100 peers
Free cash flow yield(13.5%)(1.0%)28pricier than 72 of 100 peers
Book value to price0.010.2814pricier than 86 of 100 peers
Sales to price0.170.3137pricier than 63 of 100 peers
Composite equity issuance, five years196.8%20.3%90more equity-funded than 90 of 100 peers
Relative strength against the sector, log excess return(0.04)(0.14)58ahead of 58 of 100 peers

Inputs: market equity $162.2M; EBIT -$26.6M; free cash flow -$21.9M; book equity $2.3M; sales $27.5M; debt $1.0M; cash $17.4M[22].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(82.6%)✗ fail[8,10]
Operating cash flow above zero-$21.7M✗ fail[9]
Return on assets improved(16.5 pts)✗ fail[8,10,20,23]
Operating cash flow exceeds net income$4.9M✓ pass[8-9]
Long-term leverage felln/a[1,10,20,24]
Current ratio improved90.4 pts✓ pass[11-12,25-26]
No new shares issued58.0%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improved70.2 pts✓ pass[2,10,17,20]
Cash, filings, liquidity
Cash and equivalents$17.4M[5]
Operating cash flow, four quarters-$50.0M[5,9,27-30]
Months of runway4.2
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing56
10-Q received Aug 14, 2026
Median daily dollar volume$5.0M
63 sessions
Days since newest grade input207

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$42.2M2025-12-312026-03-1610-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$27.5M2025-12-312026-03-1610-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding97,660,7912026-03-132026-03-1610-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding61,819,1012025-03-272025-03-3110-Kfiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$17.4M2026-06-302026-08-1410-Qfiling · viewer · series
6cashus-gaap:CashAndCashEquivalentsAtCarryingValue$48.5M2023-12-312025-03-3110-Kfiling · viewer · series
7total debtus-gaap:LongTermDebt$4.0M2023-12-312024-03-2810-Kfiling · viewer · series
8net incomeus-gaap:NetIncomeLoss-$26.6M2025-12-312026-03-1610-Kfiling · viewer · series
9operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$21.7M2025-12-312026-03-1610-Kfiling · viewer · series
10assetsus-gaap:Assets$32.2M2024-12-312026-03-1610-Kfiling · viewer · series
11current assetsus-gaap:AssetsCurrent$37.0M2025-12-312026-03-1610-Kfiling · viewer · series
12current liabilitiesus-gaap:LiabilitiesCurrent$13.5M2025-12-312026-03-1610-Kfiling · viewer · series
13retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$368.5M2025-12-312026-03-1610-Kfiling · viewer · series
14operating incomeus-gaap:OperatingIncomeLoss-$26.6M2025-12-312026-03-1610-Kfiling · viewer · series
15book equityus-gaap:StockholdersEquity$26.4M2025-12-312026-03-1610-Kfiling · viewer · series
16liabilitiesus-gaap:Liabilities$15.8M2025-12-312026-03-1610-Kfiling · viewer · series
17revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$9.3M2024-12-312026-03-1610-Kfiling · viewer · series
18revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$5.5M2023-12-312025-03-3110-Kfiling · viewer · series
19revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$1.2M2022-12-312024-03-2810-Kfiling · viewer · series
20assetsus-gaap:Assets$61.5M2023-12-312025-03-3110-Kfiling · viewer · series
21assetsus-gaap:Assets$91.3M2022-12-312024-03-2810-Kfiling · viewer · series
22shares outstandingdei:EntityCommonStockSharesOutstanding7,264,4142026-08-122026-08-1410-Qfiling · viewer · series
23net incomeus-gaap:NetIncomeLoss-$40.7M2024-12-312026-03-1610-Kfiling · viewer · series
24long term debtus-gaap:LongTermDebtNoncurrent$02024-12-312025-03-3110-Kfiling · viewer · series
25current assetsus-gaap:AssetsCurrent$25.1M2024-12-312026-03-1610-Kfiling · viewer · series
26current liabilitiesus-gaap:LiabilitiesCurrent$13.7M2024-12-312026-03-1610-Kfiling · viewer · series
27operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$39.9M2026-06-302026-08-1410-Qfiling · viewer · series
28operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$10.9M2026-03-312026-05-1410-Qfiling · viewer · series
29operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$20.6M2025-09-302025-11-1210-Qfiling · viewer · series
30operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$11.6M2025-06-302026-08-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.